There are 4 clinical trials
The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. Outcome will be measured as pregnancy success, live born babies and unwanted side effects.
This assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (FSHR N680S and LHR N312S) became pregnant, 40% of those with serine did (Lindgren I et al. --- N680S ---
Description: Association between pregnancy rate and genotype is evaluated
Measure: Pregnancy Time: up to 12 months after treatmentDescription: Number of eggs developed in response to drug according to genotype is measured
Measure: Number of oocytes Time: up to 6 months after treatmentDescription: Live birth rate according to genotype is analyzed
Measure: live birth Time: up to 12 months after treatmentDescription: Association between overreaction to hormonal stimulation and genotype is analysed
Measure: Ovarian hyper stimulation syndrome Time: Up to 6 months after treatmentDescription: No or poor development of eggs in response to drug is analysed, genotype taken into account
Measure: Poor response Time: Up to 6 months after treatmentAim of study: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.
To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.. polymorphisms in the FSH receptor (FSHR) variant N680S. --- N680S ---
To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.. polymorphisms in the LH receptor (LHR) variant N312S. --- N680S ---
Description: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.
Measure: Gonadotrophin receptor polymorphisms and ovarian response and AMH value Time: 1 yearDescription: To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
Measure: polymorphisms in the FSH receptor (FSHR) variant N680S Time: 1 yearDescription: To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
Measure: polymorphisms in the LH receptor (LHR) variant N312S Time: 1 yearDescription: To analyse the doses of gonadotrophins needed for stimulation on each group of patients
Measure: Doses of gonadotrophin needed and polymorphisms Time: 1 yearTo evaluate the difference in the prevalence of the main FSHR polymorphism (ASN680Ser), as well as other, less studied, gonadotropin polymorphisms between ovarian response groups, following ovarian stimulation
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response To evaluate the difference in the prevalence of the main FSHR polymorphism (ASN680Ser), as well as other, less studied, gonadotropin polymorphisms between ovarian response groups, following ovarian stimulation prevalence of the main FSH receptor polymorphism. --- ASN680Ser ---
Exploratory, prospective, randomized, comparative, open trial with control group treated to assess whether the effective use of urinary FSH (uFSH) or recombinant FSH (rFSH) can be influenced by genotype of receptor N680S FSH Gene Polymorphism.
Prospective, Randomized Open Trial to Evaluate the Efficacy of Highly Purified Urinary FSH Versus Recombinant FSH in Oocyte Donors Undergoing Controlled Ovarian Stimulation Based on Receptor N680S FSH Gene Polymorphism. --- N680S ---
Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial) Exploratory, prospective, randomized, comparative, open trial with control group treated to assess whether the effective use of urinary FSH (uFSH) or recombinant FSH (rFSH) can be influenced by genotype of receptor N680S FSH Gene Polymorphism. --- N680S ---
Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial) Exploratory, prospective, randomized, comparative, open trial with control group treated to assess whether the effective use of urinary FSH (uFSH) or recombinant FSH (rFSH) can be influenced by genotype of receptor N680S FSH Gene Polymorphism. --- N680S --- --- N680S ---
Inclusion Criteria: - Be considered eligible to get into the oocyte donation program of Instituto Bernabeu - Age between 18 and 30 years - Body Mass Index over 18 and under 28 - Antral follicle count greater than 9 and less than 25 (adding both ovaries) - Patients starting ovarian stimulation with 225 IU of FSH - Presence of both ovaries - Ability to participate and comply with the study protocol - Signing the written consent form - Not having received treatment with ovulation stimulators in the 3 months prior to stimulation Exclusion Criteria: - Not suitable for inclusion in the oocyte donation program of Institute Bernabeu - Concurrent participation in another study Inclusion Criteria: - Be considered eligible to get into the oocyte donation program of Instituto Bernabeu - Age between 18 and 30 years - Body Mass Index over 18 and under 28 - Antral follicle count greater than 9 and less than 25 (adding both ovaries) - Patients starting ovarian stimulation with 225 IU of FSH - Presence of both ovaries - Ability to participate and comply with the study protocol - Signing the written consent form - Not having received treatment with ovulation stimulators in the 3 months prior to stimulation Exclusion Criteria: - Not suitable for inclusion in the oocyte donation program of Institute Bernabeu - Concurrent participation in another study Reproductive Techniques, Assisted The aim of this study is to determine whether the number of oocytes obtained in women oocyte donors may be different with the use of rFSH or uFSH based on receptor N680S FSHR gene polymorphism. --- N680S ---
Description: number of cumulus-oocyte complexes obtained by follicle puncture at the end of ovarian stimulation
Measure: number of cumulus-oocyte complexes obtained Time: through study completion, an average of 2 weeksDescription: number of metaphase II (MII) oocytes obtained by follicle puncture at the end of ovarian stimulation
Measure: number of metaphase II (MII) oocytes Time: through study completion, an average of 2 weeksDescription: number of useful oocytes after artificial insemination or microinjection
Measure: number of useful oocytes (inseminated or microinjected) Time: through study completion, an average of 2 weeksDescription: mean number of days between the start of ovarian stimulation until the day of the follicular puncture
Measure: duration of stimulation (days) Time: through study completion, an average of 2 weeksDescription: FSH treatment units administrated per oocyte obtained
Measure: FSH treatment units obtained by oocyte Time: through study completion, an average of 2 weeksDescription: FSH treatment cost per oocyte obtained
Measure: FSH treatment cost per oocyte obtained Time: through study completion, an average of 2 weeksDescription: fertilization rate at 18 hours post-insemination
Measure: fertilization rate Time: through study completion, an average of 2 weeksDescription: occurrence of side effects associated with urinary FSH and recombinant FSH
Measure: occurrence of side effects Time: through study completion, an average of 2 weeks